AbstractVirus-like particles (VLPs) offer a platform to test the hypothesis that, since antibody binding to native envelope glycoprotein (Env) trimers results in HIV-1 neutralization, that native Env trimers presented in membranes may be useful for inducing neutralizing antibodies (nAbs) in a vaccine setting. So far, VLPs have not fulfilled this potential. Here, using a “shotgun” approach, we evaluated a wide cross-section of variables in a series of VLP immunizations. We identified 3 tentative leads. First, that VLP doses may not have been sufficient for optimal nAb induction. Second, that dampening the antigenicity of non-functional Env (for example uncleaved gp160) using either protease digests or IgG masking may be useful. Third, that g...
<div><p>The native-like, soluble SOSIP.664 trimer based on the BG505 clade A <i>env</i> gene of HIV-...
A fundamental challenge for developing an effective and safe HIV-1 vaccine is to identify vaccine im...
Human immunodeficiency virus type 1 (HIV-1) vaccine development requires selection of appropriate en...
AbstractVirus-like particles (VLPs) offer a platform to test the hypothesis that, since antibody bin...
AbstractTo assess the potential of native Envelope glycoprotein (Env) trimers as neutralizing antibo...
Abstract An effective human immunodeficiency virus type I (HIV-1) vaccine that robustly elicits broa...
BACKGROUND: Ten to 30% of HIV-1 infected subjects develop broadly neutralizing antibodies (bNAbs) du...
Ten to 30% of HIV-1 infected subjects develop broadly neutralizing antibodies (bNAbs) during chronic...
Summary: Despite recent progress in engineering native trimeric HIV-1 envelope glycoprotein (Env) mi...
The high viral diversity of HIV-1 is a formidable hurdle for the development of an HIV-1 vaccine. El...
Recombinant soluble HIV-1 envelope glycoprotein (Env) SOSIP trimers are a design platform for induci...
Evaluating the structure-function relationship of viral envelope (Env) evolution and the development...
After over 35 years of research, a prophylactic HIV vaccine remains elusive. However, the discovery ...
© 2017 Dr Christopher Andrew GonelliA prophylactic vaccine eliciting broadly neutralising antibody (...
Abstract An effective HIV-1 vaccine probably will need to be able to induce broadly neutralizing HIV...
<div><p>The native-like, soluble SOSIP.664 trimer based on the BG505 clade A <i>env</i> gene of HIV-...
A fundamental challenge for developing an effective and safe HIV-1 vaccine is to identify vaccine im...
Human immunodeficiency virus type 1 (HIV-1) vaccine development requires selection of appropriate en...
AbstractVirus-like particles (VLPs) offer a platform to test the hypothesis that, since antibody bin...
AbstractTo assess the potential of native Envelope glycoprotein (Env) trimers as neutralizing antibo...
Abstract An effective human immunodeficiency virus type I (HIV-1) vaccine that robustly elicits broa...
BACKGROUND: Ten to 30% of HIV-1 infected subjects develop broadly neutralizing antibodies (bNAbs) du...
Ten to 30% of HIV-1 infected subjects develop broadly neutralizing antibodies (bNAbs) during chronic...
Summary: Despite recent progress in engineering native trimeric HIV-1 envelope glycoprotein (Env) mi...
The high viral diversity of HIV-1 is a formidable hurdle for the development of an HIV-1 vaccine. El...
Recombinant soluble HIV-1 envelope glycoprotein (Env) SOSIP trimers are a design platform for induci...
Evaluating the structure-function relationship of viral envelope (Env) evolution and the development...
After over 35 years of research, a prophylactic HIV vaccine remains elusive. However, the discovery ...
© 2017 Dr Christopher Andrew GonelliA prophylactic vaccine eliciting broadly neutralising antibody (...
Abstract An effective HIV-1 vaccine probably will need to be able to induce broadly neutralizing HIV...
<div><p>The native-like, soluble SOSIP.664 trimer based on the BG505 clade A <i>env</i> gene of HIV-...
A fundamental challenge for developing an effective and safe HIV-1 vaccine is to identify vaccine im...
Human immunodeficiency virus type 1 (HIV-1) vaccine development requires selection of appropriate en...